Acquired epidermodysplasia verruciformis: clinical presentation and treatment update
- PMID: 34403500
- DOI: 10.1111/ijd.15857
Acquired epidermodysplasia verruciformis: clinical presentation and treatment update
Abstract
Acquired epidermodysplasia verruciformis (AEV) is a form of epidermodysplasia verruciformis (EV) that is most commonly found in immunocompromised or immunosuppressed patients. EV is commonly associated with human papillomavirus (HPV), which is often found in EV and AEV lesions. Clinical presentation of AEV in patients with organ transplantation, HIV+, congenital HIV+, hematological diseases, and other iatrogenic immunosuppression are reviewed. Treatment options include topical cidofovir, topical retinoids, topical imiquimod, topical glycolic acid, HPV 9-valent vaccine, acitretin, improving cellular immunity, and changing transplant medication to mycophenolate mofetil.
© 2021 the International Society of Dermatology.
References
-
- Huang S, Wu JH, Lewis DJ, et al. A novel approach to the classification of epidermodysplasia verruciformis. Int J Dermatol 2018; 57: 1344-1350.
-
- Myers DJ, Fillman EP Epidermodysplasia verruciformis. In StatPearls [Internet]. StatPearls Publishing; 2019.
-
- Prose NS, von Knebel-Doeberitz C, Miller S, et al. Widespread flat warts associated with human papillomavirus type 5: a cutaneous manifestation of human immunodeficiency virus infection. J Am Acad Dermatol 1990; 23(5 Pt 2): 978-981.
-
- Rogers HD, MacGregor JL, Nord KM, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009; 60: 315-320.
-
- da Cruz Silva LL, de Oliveira WRP, Sotto MN. Epidermodysplasia verruciformis: revision of a model of carcinogenic disease. Surg Exp Pathol 2019; 2: 20.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
